Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10718454 | 0.86 | FKBP5 (0.42) | MAOAMAOBALDH1A1KDM4EHSD17B10 | |
| SCHEMBL10927335 | 0.86 | MAOA (0.41) | MAOAMAOBALDH1A1KDM4EHSD17B10 | |
| SCHEMBL1493436 | 0.84 | MAOA (0.39) | MAOAMAOBALDH1A1KDM4EHSD17B10 | |
| SCHEMBL8482200 | 0.81 | CA12 (0.41) | MAOAMAOBALDH1A1KDM4EHSD17B10 | |
| SCHEMBL6620118 | 0.81 | MAOB (0.37) | MAOAMAOBALDH1A1KDM4EGAA | |
| SCHEMBL8486535 | 0.80 | HSD17B10 (0.40) | MAOAMAOBALDH1A1KDM4EHSD17B10 | |
| SCHEMBL8482832 | 0.78 | KMT2A (0.46) | ALDH1A1KDM4EHPGDNOTUMMAPK1 | |
| SCHEMBL10931533 | 0.75 | MAOA (0.37) | MAOAMAOBALDH1A1KDM4EHSD17B10 | |
| SCHEMBL4244976 | 0.75 | AKR1B1 (0.39) | MAOAMAOBALDH1A1KDM4EHSD17B10 | |
| SCHEMBL2075820 | 0.73 | MAOA (0.46) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618977-B2 | Method of treating dermatitis comprising administering a chymase inhibitor | ASUBIO PHARMA CO., LTD. (JP) | 2009-11-17 | — | — | US | claimed |
| EP-1174151-B1 | THERAPEUTIC TREATMENT OF EOSINOPHILIA USING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2007-01-24 | — | — | EP | claimed |
| US-6677344-B2 | Chymase inhibitor for the treatment of eosinophilia | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-01-13 | — | — | US | claimed |
| US-6500835-B2 | FOR PROPHYLAXIS AND THERAPY OF FIBROSIS INVOLVING EXTRACELLULAR MATRIX DYSBOLISM HAVING A CHYMASE INHIBITOR AS AN EFFECTIVE INGREDIENT; SIDE EFFECT REDUCTION | SUNTORY LIMITED (JP) | 2002-12-31 | — | — | US | claimed |
| US-5952494-A | Method for the preparation of pyrido benzoxazine derivatives | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1999-09-14 | — | — | US | claimed |
| CN-1079744-A | 7-oxo-7H-pyrido [1,2,3 ,-d, e] [1,4] benzoxazine-6-carboxylic acids and ester thereof | BAYER AG (DE) | 1993-12-22 | — | — | CN | claimed |
| JP-61161281-A | — | — | None | — | — | JP | disclosed |
| US-9783511-B2 | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160311787-A1 | CARBAMATE BENZOXAZINE PROPIONIC ACIDS AND ACID DERIVATIVES FOR MODULATION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2016-10-27 | — | — | US | disclosed |
| WO-2015095792-A1 | CARBAMATE BENZOXAXINE PROPIONIC ACIDS AND ACID DERIVATIVES FOR MODULATION OF RORGAMMA ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | ASUBIO PHARMA CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-7618977-B2 | Method of treating dermatitis comprising administering a chymase inhibitor | ASUBIO PHARMA CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1142586-B1 | USE OF CHYMASE INHIBITORS AGAINST VASCULAR LIPID DEPOSITION | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2007-04-25 | — | — | EP | disclosed |
| EP-0184035-B1 | QUINOLONECARBOXYLIC ACID DERIVATIVES AND PROCESS FOR THEIR PREPARATION | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1990-07-25 | — | — | EP | disclosed |
| EP-0305744-A3 | QUINOLINE, NAPHTHYRIDINE AND BENZOXAZINE-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1990-05-30 | — | — | EP | disclosed |
| US-4923879-A | CARBOXYLIC ACID DERIVATIVES WITH BRIDGED SIDECHAINS | WARNER-LAMBERT COMPANY (US) | 1990-05-08 | — | — | US | disclosed |
| EP-0305744-A2 | Quinoline, naphthyridine and benzoxazine-carboxylic acid derivatives and their use as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1989-03-08 | — | — | EP | disclosed |
| EP-0305744-A2 | Quinoline, naphthyridine and benzoxazine-carboxylic acid derivatives and their use as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1989-03-08 | — | — | EP | disclosed |
| CN-86106385-A | The bridge-type diazonium bicyclic alkyl quinolone carboxylic acid that replaces | — | 1987-06-03 | — | — | CN | disclosed |
| JP-S61161281-A | 1,2-BENZOTHIAZINE-3-CARBOXAMIDE DERIVATIVE | GRELAN PHARMACEUT CO LTD | 1986-07-21 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311787-A1 | CARBAMATE BENZOXAZINE PROPIONIC ACIDS AND ACID DERIVATIVES FOR MODULATION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | MAOA 4389/4885MAOB 4297/4885ALDH1A1 350/4885 |
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | CMA1, DNPEP, SERPINB1 | MAOA 784/4885MAOB 1449/4885ALDH1A1 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.